[Osteoarthritis and COX-2 inhibitors]

[Article in Danish]

Comparative Study

[Article in Danish]

Mats Lindberg. Ugeskr Laeger. 2002.

. 2002 Aug 12;164(33):3874.

No abstract available

Comment on

[Osteoarthritis. Pathogenesis, clinical features and treatment].
Veje K, Hyllested JL, Østergaard K. Veje K, et al. Ugeskr Laeger. 2002 Jun 10;164(24):3173-9. Ugeskr Laeger. 2002. PMID: 12082761 Review. Danish.

[Treatment of osteoarthritis with COX-2 inhibitors: good for the stomach, but bad for the patient?].
Andersen SE. Andersen SE. Ugeskr Laeger. 2002 Aug 12;164(33):3874-5. Ugeskr Laeger. 2002. PMID: 12216163 Danish. No abstract available.
[Osteoarthritis].
Unkerskov J, Glintborg D, Bach KF, Kampmann JP. Unkerskov J, et al. Ugeskr Laeger. 2002 Aug 12;164(33):3875; author reply 3875-6. Ugeskr Laeger. 2002. PMID: 12216164 Danish. No abstract available.
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN, Callaghan R, Allen ME, Rowe IF. Price-Forbes AN, et al. Rheumatology (Oxford). 2005 Jul;44(7):921-4. doi: 10.1093/rheumatology/keh642. Epub 2005 Apr 12. Rheumatology (Oxford). 2005. PMID: 15827035
The COX 2 selective inhibitors: what the newspapers have not told you.
Simon LS. Simon LS. Bull NYU Hosp Jt Dis. 2007;65(3):229-41. Bull NYU Hosp Jt Dis. 2007. PMID: 17922675 Review. No abstract available.
Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ, Schwartz BD. Mengle-Gaw LJ, et al. Mediators Inflamm. 2002 Oct;11(5):275-86. doi: 10.1080/09629350290000041. Mediators Inflamm. 2002. PMID: 12467519 Free PMC article. Review.